1338 results about "High avidity" patented technology

The invention relates to a mouse anti-PBP2a hybridoma cell strain, a monoclonal antibody and application of the mouse anti-PBP2a hybridoma cell strain, staphylococcus aureus PBP2a protein is extracted as an antigen, after the high-purity antigen is obtained, a good immunoreaction is aroused in a mouse body, then a hybridoma technology is adopted, two cell strains with high affinity and specificity are screened, and the corresponding antibody is prepared; the two antibodies are used as a gold-labeled antibody and a coating antibody in a colloidal gold immunoassay kit, and the kit can be used for detecting PBP2a protein in methicillin-resistant staphylococcus aureus and can be used for developing related in-vitro diagnostic reagents.

The invention belongs to the technical field of polypeptides, and discloses a polypeptide targeting HER2 protein, a radioactive polypeptide and a preparation method and application of the radioactive polypeptide, and the structural formula of the radioactive polypeptide is as follows: # imgabs0 #. Through in-vitro radiochemical property research and in-vivo stability research, the 68Ga-DOTA-AON is found to be high in stability and hydrophilic; through cell uptake research and receptor binding force research, the 68Ga-DOTA-AON is found to have relatively high affinity to HER2 protein expressed by HT-29 cells; the tumor imaging effect of the radioactive polypeptide 68Ga-DOTA-AON is investigated through small animal PET / CT, and it is found that [68Ga] Ga-DOTA-AON can be used for in-vivo imaging of HER2 positive colorectal cancer.

The invention relates to the technical field of biological medicines, and particularly discloses an anti-human CD3 rabbit recombinant monoclonal antibody as well as a preparation method and application thereof. The antibody obtains anti-CD3 immune response by immunizing a rabbit, is obtained by combining single B cell sorting, gene cloning and a mammalian cell expression system, and has high affinity and good specificity. The antibody can effectively recognize CD3 positive T cells in human peripheral blood and can be applied to the fields of flow cytometry, immunohistochemistry, T cell function research and the like. Experimental results show that the antibody has the advantages of high titer, strong fluorescence signal, low background and the like, and is superior to the traditional murine anti-CD3 antibody. Amino acid sequences of light chain and heavy chain variable regions of the antibody are further obtained, and controllability and repeatability of antibody expression are achieved. The antibody has important scientific research value and industrial application prospect, and is suitable for various scenes such as T cell marker detection, immune state evaluation, immunotherapy auxiliary research and the like.

The invention belongs to the field of antibodies, and particularly relates to an anti-NMP22 monoclonal antibody as well as a preparation method and application thereof. The invention provides CDR sequences of a heavy chain variable region and a light chain variable region of an anti-NMP22 antibody, the antibody can specifically recognize nuclear matrix protein 22 (NMP22), has high affinity and high specificity to the protein, can be applied to diagnosis of diseases related to abnormal urine nuclear matrix protein 22 level, and especially can be applied to clinical diagnosis of bladder cancer.

The invention relates to the technical field of biology, in particular to a preparation method and application of an anti-human MUC1 antibody, and provides a recombination system which utilizes an in-vitro B cell culture technology, uses ELISA (enzyme-linked immunosorbent assay) to detect the expression condition of the antibody, performs flow detection on the binding capacity level with cells and performs antibody expression and assembly through an expression vector. The monoclonal antibody with high specificity and strong affinity is screened out, and the immunogenicity is reduced on the basis that the high affinity combined with the antigen is reserved through humanized transformation, so that the monoclonal antibody is favorably applied to immunotherapy of a human body; the anti-human MUC1 antibody prepared by the invention plays an important role in immunotherapy of tumors, and solves the technical problems of insufficient specificity and lower affinity of the MUC1 antibody in the prior art.

The present application provides anti-B7-H3 monoclonal antibodies, in particular, high affinity B7-H3 humanized monoclonal antibodies having cross-activity with humans, cynomolgus monkeys and mice, as well as nucleic acids encoding the antibodies, vectors comprising the nucleic acids, and host cells comprising the nucleic acids or vectors. Also disclosed are pharmaceutical compositions and conjugates comprising the antibodies, as well as uses of the antibodies.

The invention relates to an anti-CD3 nano antibody, an anti-CD38 antibody and a bispecific antibody containing the anti-CD3 nano antibody and the anti-CD38 antibody. According to the invention, an anti-CD3 nano antibody and an anti-CD38 monoclonal antibody are excavated and prepared, humanized design is carried out to obtain antibodies with high affinity and specificity, and different configurations of bispecific T cell conjugation antibodies targeting CD3 and CD38 are further designed, so that the CD3 and CD38 dual-specificity T cell conjugation antibodies are obtained. The antigen binding activity, the T cell-mediated tumor cell killing effect and the T cell proliferation and activation function of the antibody are systematically evaluated in vitro, and experimental results show that the T cell conjugation antibody can effectively recruit and activate T cells and has a remarkable killing effect on CD38 positive tumor cells, and it is further verified that the antibody has remarkable in-vivo anti-tumor activity and has a good application prospect. Therefore, the polypeptide has high affinity, good pharmacological characteristics and development potential.

The invention belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody combination for detecting measles virus nucleoprotein and application of the monoclonal antibody combination. The combination is composed of monoclonal antibodies 5E2 and 5G9 and can efficiently and specifically recognize measles virus nucleoprotein, amino acid sequences of complementary determining regions (CDR) of heavy chain and light chain variable regions of the combination are clear and are shown as SEQ ID NO.1-12 respectively, high specificity and high affinity of the antibodies are guaranteed, the antibody combination can effectively capture and detect target antigens, and the antibody combination can be used for detecting measles virus nucleoprotein. The risk of non-specific binding and cross reaction is obviously reduced. The combination shows excellent sensitivity and specificity in detection platforms such as colloidal gold immunochromatography, and provides a stable and reliable biological recognition tool for rapid and accurate detection of measles viruses.

The invention belongs to the technical field of biomedicine, and particularly relates to a nano antibody aiming at influenza A virus H1N1 subtype NA protein and application. The nano antibody comprises an amino acid sequence as shown in SEQ ID NO: 1 or consists of the amino acid sequence as shown in SEQ ID NO: 1. The nano antibody has high affinity, and experimental results show that the antibody can effectively inhibit proliferation of PR8 H1N1 virus in vivo and resist infection of lethal dose virus on mice. Meanwhile, the nano antibody is the first nano antibody which aims at the N1 subtype NA protein and has prevention and treatment effects, the market blank is filled, and the nano antibody can be applied to the fields of laboratory research, biosensor development, clinical diagnosis, infection prevention and treatment and the like. The nano antibody provided by the invention has the advantages of small molecular weight, high stability, low production cost and the like, and has wider application potential and market competitive advantages compared with the traditional IgG antibody.

The present invention provides nucleic acid molecules that encode antibodies or antigen-binding fragments thereof, which specifically bind human interleukin-4 receptor (IL-4R). Also provided are expression vectors comprising nucleic acid molecule that encode anti-IL-4R antibodies, host cells comprising the expression vectors, and methods of producing anti-IL-4R antibodies or antigen-binding fragments thereof comprising growing the host cells under conditions permitting production of the antibody or fragment, and recovering the antibody or fragment so produced.

A series of novel anti-B7-H3 antibodies. The antibodies have high affinity to B7-H3 and have stable structures. Also provided is an antibody drug conjugate prepared by using said antibody. The antibody drug conjugate uses a camptothecin compound having a specific structure as a toxic molecule, has significant tumor inhibition activity, and has a bystander killing effect.

The invention belongs to the field of drug design, and particularly discloses a virtual screening method of a small-molecule inhibitor targeting YTHDF1 protein, which comprises the following steps: acquiring a YTHDF1 protein structure, and carrying out homologous modeling to generate various conformation proteins; small molecules combined with the YTHDF1 protein are obtained, bait molecules are generated, and ligand molecules are formed; a ligand molecule is in butt joint with a binding site on the YTHDF1, and the compound is characterized through PLEC fingerprints; the method comprises the following steps: constructing a specificity scoring function by using a machine learning algorithm, carrying out scoring screening on a compound to be screened and a compound butted with YTHDF1 molecules, carrying out affinity prediction, and screening out the small-molecule inhibitor targeting YTHDF1. According to the virtual screening method provided by the invention, the YTHDF1 targeting molecules with high affinity can be accurately screened on a large scale, candidate molecules are provided for research and development of medicines for treating YTHDF1 related diseases, and a foundation is laid for clinical tests and medicine optimization.

The invention discloses an anti-rabbit IgG goat recombinant monoclonal antibody as well as preparation and application thereof, and belongs to the technical field of biology. The recombinant monoclonal antibody is obtained by taking purified rabbit serum IgG as an immunogen, immunizing a goat, carrying out specific B cell screening and RT-PCR (Reverse Transcription-Polymerase Chain Reaction) to obtain a heavy chain variable region and a light chain variable region of the antibody, respectively inserting sequences of the variable regions into vector plasmids with constant region (heavy chain and light chain) genes, transfecting, expressing and purifying. The recombinant monoclonal antibody provided by the invention has high affinity with rabbit IgG, can recognize and detect rabbit IgG with high specificity and high sensitivity, can be used as a secondary antibody after HRP crosslinking, is applied to detection of rabbit IgG by methods such as western blot, immunohistochemistry and ELISA, is beneficial to obtaining more accurate detection and evaluation results, and has good application prospects. And the detection cost and the interference of background signals are reduced.

The present invention provides an antibody binding to human CD73, a preparation method therefor, and a use thereof. The monoclonal antibody of the present invention can bind to a CD73 antigen with high specificity, has high affinity, has remarkable anti-tumor activity and the like, and has excellent clinical application prospects.

The invention discloses a novel coronavirus neutralizing antibody, a detection kit and application of the novel coronavirus neutralizing antibody. The amino acid sequence of a heavy chain variable region of the neutralizing antibody is shown as SEQ ID No.1, and the amino acid sequence of a light chain variable region of the neutralizing antibody is shown as SEQ ID No.2. The antibody with mature affinity is screened through bioinformatics analysis of a single B cell, the antibody screening process is optimized by combining single cell RNA sequencing, VDJ rearrangement analysis and somatic cell hypermutation research, blindness of a traditional method is avoided, and the accuracy and effectiveness of antibody screening are improved. According to the neutralizing antibody GR12 provided by the invention, a heavy chain variable region and a light chain variable region of the neutralizing antibody GR12 can be specifically combined with an RBD structural domain of the SARS-CoV-2 and an S-Trimer structural domain of an Omicro variant, so that a broad-spectrum neutralizing effect on the SARS-CoV-2 virus and the variant thereof is realized. The binding activity of the antibody GR12 to S-Trimer and RBD under 2-fold and 300-fold dilution conditions is obviously superior to that of other antibodies, which indicates that the antibody GR12 has high affinity and dilution stability and is suitable for clinical large-dose administration.

The present invention discloses a nucleic acid aptamer that specifically recognizes DEHP and its application, and belongs to the field of environmental safety biotechnology. The nucleic acid aptamer is any one of the following: (1) a single-stranded DNA sequence such as a nucleotide sequence shown in SEQ ID No.10; (2) a sequence that uses the nucleotide sequence shown in SEQ ID No.10 as a core sequence, is extended or shortened on both sides or on one side, and has the same function as the nucleotide sequence described in (1). The present invention is based on Capture‑SELEX technology, and after 10 rounds of repeated screening, a nucleic acid aptamer SEQ ID No.10 that can bind to DEHP with high affinity and high specificity is finally obtained. The nucleic acid aptamer is applied to the DEHP detection of actual samples, which has important application prospects for the analysis and detection of DEHP in blood samples, cell samples, food and drinking water.

Disclosed are an artificial hapten and artificial antigen of fentanyl, and a preparation method and application thereof. The artificial hapten of fentanyl according to the invention has an active group capable of being coupled with a carrier protein, and can be used as an antigenic determinant; and the artificial antigen of fentanyl further prepared can be immunized to obtain an anti-fentanyl antibody with high affinity, high sensitivity and strong specificity, and the antigen-antibody can be used in enzyme-linked immunity, immunochromatography and other technologies.

The invention discloses a novel coronavirus neutralizing antibody, a detection kit and application of the novel coronavirus neutralizing antibody. The amino acid sequence of a heavy chain variable region of the neutralizing antibody is shown as SEQ ID No.1, and the amino acid sequence of a light chain variable region of the neutralizing antibody is shown as SEQ ID No.2. The antibody with mature affinity is screened through bioinformatics analysis of a single B cell, the antibody screening process is optimized by combining single cell RNA sequencing, VDJ rearrangement analysis and somatic cell hypermutation research, blindness of a traditional method is avoided, and the accuracy and effectiveness of antibody screening are improved. According to the neutralizing antibody GR75 provided by the invention, a heavy chain variable region and a light chain variable region of the neutralizing antibody GR75 can be specifically combined with an RBD structural domain of the SARS-CoV-2 and an S-Trimer structural domain of an Omicro variant, so that a broad-spectrum neutralizing effect on the SARS-CoV-2 virus and the variant thereof is realized. The binding activity of the antibody GR75 to S-Trimer and RBD under 2-fold and 300-fold dilution conditions is obviously superior to that of other antibodies, which indicates that the antibody GR75 has high affinity and dilution stability and is suitable for clinical large-dose administration.

The invention discloses a deep mutation scanning method based on protein-protein interaction in bacterial cells and a binding affinity prediction method. In the invention, split dCas9 proteins (SEQ ID NO.1 and SEQ ID NO.2) are respectively subjected to fusion expression with a receptor and a ligand with binding affinity to be detected, and are combined with a toxic sgRNA guide sequence (SEQ ID NO.3), and when PPI occurs, a toxic dCas9: sgRNA complex is formed to inhibit bacterial growth, so that a PPI affinity size signal is converted into a bacterial cell generation speed signal, and the signal can be quantified into a copy number value through next-generation sequencing. The invention further designs a deep learning binding affinity prediction model, high-affinity sequences can be screened from theoretical mutation space, the workload and cost of experimental verification are remarkably reduced, and a reliable basis is provided for subsequent protein function optimization and design.

Related to the field of disease treatment, and provided are bispecific antibodies against EGFR and c-MET, nucleic acid molecules encoding them, and methods for preparing them. Said anti-EGFR and c-MET bispecific antibodies have high specificity and high affinity for EGFR and c-MET. Also provided is the use of said bispecific antibodies in the treatment and diagnosis of diseases.

The invention provides an ORM1 and CEA protein antibody, a combination of the ORM1 and CEA protein antibody and an application of the ORM1 and CEA protein antibody in colorectal cancer diagnosis, and aims to effectively solve the problems of low affinity and specificity and poor stability of the existing antibody by optimizing the immunogen sequences of ORM1 and CEA, screening a monoclonal antibody with high affinity and high specificity, screening the optimal ORM1 and CEA antibody and combining the optimal ORM1 and CEA antibody. The kit has a wide detection range, shows an extremely high collaborative diagnosis value during combined detection, remarkably improves the diagnosis efficiency of early colorectal cancer, and has an important clinical application value.

The invention discloses a novel coronavirus neutralizing antibody GR46, a detection kit and application of the novel coronavirus neutralizing antibody GR46. The amino acid sequence of a heavy chain variable region of the neutralizing antibody is shown as SEQ ID No.1, and the amino acid sequence of a light chain variable region of the neutralizing antibody is shown as SEQ ID No.2. The antibody with mature affinity is screened through bioinformatics analysis of a single B cell, the antibody screening process is optimized by combining single cell RNA sequencing, VDJ rearrangement analysis and somatic cell hypermutation research, blindness of a traditional method is avoided, and the accuracy and effectiveness of antibody screening are improved. According to the neutralizing antibody GR46 provided by the invention, a heavy chain variable region and a light chain variable region of the neutralizing antibody GR46 can be specifically combined with an RBD structural domain of the SARS-CoV-2 and an S-Trimer structural domain of an Omicro variant, so that a broad-spectrum neutralizing effect on the SARS-CoV-2 virus and the variant thereof is realized. The binding activity of the antibody GR46 to S-Trimer and RBD under 2-time and 300-time dilution conditions is obviously superior to that of other antibodies, which indicates that the antibody GR46 has high affinity and dilution stability and is suitable for clinical large-dose administration.

The invention relates to an anti-human PD-1 shark nano antibody and application thereof, and belongs to the technical field of biology. The anti-human PD-1 shark nano antibody provided by the invention is only composed of a heavy chain, the heavy chain comprises a heavy chain variable region, and the antibody heavy chain variable region vNAR comprises CDR1 and CDR3; cDR1 is amino acid residues 25-32 in the amino acid sequence as shown in SEQ ID NO: 2; cDR3 is amino acid residues 84-102 in the amino acid sequence as shown in SEQ ID NO: 2. The invention also provides a coding nucleic acid, an expression vector, a host cell and the like of the anti-human PD-1 shark nano antibody, and also provides a production method and application of the nano antibody. The nano antibody has the advantages of high affinity, high specificity and the like, can effectively block a PD-1 / PD-L1 pathway, and has the potential of being applied to the field of tumor treatment and diagnosis.

The present invention discloses a nucleic acid aptamer binding to CD5 protein, the sequence of which is shown in SEQ ID NO.1 to SEQ ID NO.6, and by improving the screening conditions, a nucleic acid aptamer with small molecular weight, stable chemical properties, easy storage and labeling, which can bind to CD5 protein with high affinity, is screened and obtained. The aptamer is measured by surface plasmon resonance (SPR) and dot hybridization experiments to have high affinity and high specificity, and can be used in detection, diagnosis, imaging and treatment, and has broad application prospects.

The invention discloses a monoclonal antibody H2 specifically bound with a lung cancer marker CYFRA21-1 and application, and relates to the technical field of biological medicines. The method comprises the following steps: firstly, screening from a Tomlinson I + J phage library by utilizing a phage display technology to obtain a lung cancer marker CYFRA21-1 monoclonal antibody H2, and the antibody has a heavy chain complementary determining region and a light chain complementary determining region which are formed by novel amino acid sequences and can be specifically combined with CYFRA21-1 protein; the monoclonal antibody H2 of the lung cancer marker CYFRA21-1 has the characteristics of high affinity, high specificity, stability and the like, and the monoclonal antibody H2 of the lung cancer marker CYFRA21-1 not only can efficiently and accurately detect the concentration of CYFRA21-1 protein, but also can be used for immunostaining of lung cancer tumor cells and lung cancer tissues in pathological diagnosis, and has important significance for detecting the concentration of CYFRA21-1.

The invention belongs to the technical field of biological medicine and molecular biology, and particularly relates to a single-chain antibody targeting NRP1, a CAR-T cell and application of the single-chain antibody and the CAR-T cell in fibrosis treatment. Four types of high-affinity single-chain antibodies targeting mouse NRP1 antigens are obtained by immunizing mice, the single-chain antibodies are applied to second-generation CAR, T cells of mouse spleen sources are infected after virus packaging, and CAR-T cells are constructed. The CAR-T cells of the targeted NRP1 can be used for effectively killing NRP1 positive cells. In-vivo experiments show that the CAR-T cells can inhibit the growth of NRP1 positive tumor cells. The CAR-T cell can improve the mouse liver fibrosis condition, collagen in the mouse liver is reduced through treatment, and the molecular level of fibrosis markers SMA and NRP1 is reduced, it is indicated that the CAR-T cell recognizes and eliminates activated HSCs through targeting NRP1, and the fibrosis degree is reduced.

The present application is directed to methods and compositions that are useful for reducing the number of myeloid-derived suppressor cells (MDSC), tumor associated macrophages (TAM), or both in a subject. The methods include administering an antigen binding protein that binds to an antigen expressed by MDSC and / or TAM, or administering a modified T cell or NK-92 cell that expresses an antigen binding protein that binds to an antigen expressed by MDSC and / or TAM, or a combination of both, to a subject. For example, the antigen binding protein can bind to CD33 expressed by MDSC and / or TAM. The methods and compositions are useful for treating a disease associated with MDSC and / or TAM infiltration into a tissue or tumor.

The invention relates to genetically encoded fusion proteins comprised of a capture component that binds a target with high affinity and a peptide polymer, such as elastin-like polypeptides, that display phase behavior and can be used for purification. The invention further relates to methods for optimizing capture fusion proteins for individual biologic targets such that phase separation occurs under desirable conditions, such as at room temperature, lower concentrations of salt, and / or at suitable pH ranges and optimized capture domains and polypeptides with phase behavior that have been identified by the optimization methods.

The invention relates to the technical field of antibodies, in particular to an anti-African swine fever virus p30 protein monoclonal antibody and application thereof, and the anti-African swine fever virus p30 protein monoclonal antibody can be specifically combined with African swine fever virus p30 protein. The anti-ASFV p30 protein monoclonal antibody is prepared by immunizing a BALB / c mouse through an immunological method, and the antibody is high in specificity, titer and affinity and can be applied to immunological detection or antibody detection kits.

The invention discloses a nano antibody capable of specifically recognizing staphylococcus aureus as well as a preparation method and application of the nano antibody. A ribosome display technology is adopted, a nano antibody pair with a good pairing effect is screened out through construction of a nano antibody display library, three rounds of high-throughput screening and ELISA verification, and the nano antibody pair is used for in-vivo detection of actual pathogenic bacteria in combination with an immunochromatography technology. The nano antibody disclosed by the invention shows high affinity, high specificity and achievable detection limit when being combined with staphylococcus aureus, has the advantages of good stability, low cost and the like compared with a monoclonal antibody, can be produced on a large scale, and has a wide application prospect in the field of staphylococcus aureus detection and analysis.